Press Release

<< Back
Mar 01, 2012



Broad-Spectrum, Cancer-Targeting Therapeutic and Diagnostic Agents Described

MADISON, WI, March 1, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that three scientific posters based on research conducted by Jamey Weichert, Ph.D., and his colleagues will be presented at the American Association for Cancer Research (AACR) annual meeting in April, 2012 in Chicago. These presentations will describe findings in animal and cellular model systems that illustrate Novelos’ cancer-targeting technology platform and the resulting clinical-stage diapeutic agents capable of imaging and treating a wide range of malignancies. An abstract of each presentation will be published in the 2012 Proceedings of the AACR. Dr. Weichert is the Chief Scientific Officer of Novelos, founder of Novelos’ technology, and is an Associate Professor of the Department of Radiology in the School of Medicine and Public Health at the University of Wisconsin, Madison. Dr. Weichert and his University colleagues are all members of the UW Carbone Cancer Center.

Download PDF

I-124-CLR1404 and I-131-CLR1404: Broad spectrum diapeutic agents for cancer cell-targeted PET imaging and molecular radiotherapy (Abstract #5740) Dr. Weichert and his colleagues will present data appearing to demonstrate broad spectrum, selective uptake and retention of the chemical structure shared by I-124-CLR1404 (LIGHT), a PET imaging agent, and I-131- CLR1404 (HOT), a cytotoxic molecular radiotherapeutic, in human cancer cells and in vivo tumor models. This diapeutic agent may enable a personalized approach to diagnosis, treatment planning and subsequent therapy in a wide range of cancer types.

I-131-CLR1404 and CLR1404: Broad spectrum, cancer-targeted molecular radio- and chemotherapeutic phospholipid ether analogs (Abstract #3831) The second presentation by Dr. Weichert and his colleagues will report on data appearing to demonstrate the efficacy of I-131- CLR1404 (HOT) and CLR1404 (COLD), the non-radioactive and, at higher dose levels, Aktinhibiting version of the same chemical structure, in a wide variety of human xenograft models. The cancer-targeting properties of these agents may minimize damage to normal cells and tissues, which would result in favorable therapeutic indices.

The novel phospholipid ether analog CLR1404 decreases glioblastoma stem cell proliferation, suppresses GBM growth, and improves survival (Abstract #3495) Dr. Weichert, John Kuo, M.D., Ph.D., Assistant Professor of the Department of Neurological Surgery, and their colleagues’ presentation will describe data appearing to demonstrate the ability of CLR1404 (COLD) to selectively target human glioma stem cells, in vitro and in vivo, in addition to mature glioma cells and to inhibit their proliferation. Suppression of cancer stem cells could offer therapeutic advantages including fewer metastases and decreased probability of cancer relapse following treatment.

“We believe the data being presented at the AACR Annual Meeting collectively describe the ability of our optimized phospholipid ether analogs to selectively target cancer cells and cancer stem cells and also describe their underlying, lipid raft-based targeting mechanism,” said Dr. Weichert. “We further believe the resulting array of clinical-stage PET-imaging and radiotherapeutic agents, as well as a preclinical-stage chemotherapeutic, has the potential to be a unique diapeutic approach to cancer diagnosis and therapy in a wide range of indications.”

About the UW Carbone Cancer Center in Madison
The University of Wisconsin Carbone Cancer Center (UWCCC) is recognized throughout the nation as one of the leading innovators in cancer research, quality patient care and active community involvement. It is the only comprehensive cancer center, as designated by the National Cancer Institute, in Wisconsin. An integral part of the UW School of Medicine and Public Health, the UWCCC unites physicians and scientists who work together in translating discoveries from research laboratories into new treatments that benefit cancer patients. To learn more about clinical studies and other initiatives, visit

About Novelos Therapeutics, Inc.
We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer. Our three cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells. Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. I-124-CLR1404 (LIGHT) is a small-molecule cancer-targeted PET imaging agent. We believe LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing. I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. We believe HOT also has first-inclass potential. HOT Phase 1b dose-escalation trial is ongoing and we expect HOT to enter Phase 2 trials in the first quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need, subject to additional funding. CLR1404 (COLD), a cancer-targeted nonradioactive chemotherapy, works primarily through Akt inhibition. We plan to file an IND for COLD in the first quarter of 2013, subject to additional funding. Together, we believe our compounds are able to “find, treat and follow” cancer anywhere in the body in a novel, effective and highly selective way. For additional information please visit

J. Patrick Genn, Vice President of IR
Novelos Therapeutics, Inc.
Ph: (858) 775-7456

Anne Marie Fields, Senior Vice President
Lippert/Heilshorn & Associates, Inc.
Ph: (212) 838-3777
Email:, @LHA_IR_PR

Novelos Therapeutics, Inc. 
Madison, WI Boston, MA

This news release contains forward-looking statements. You can identify these statements by our use of words such as “may,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” “continue,” “plans,” or their negatives or cognates. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators’ ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.